| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 2.40 | 26.3% |
| Total Income | 2.40 | 26.3% |
| Expenditure | 6.97 | 40.5% |
| PBT | -4.54 | 50.8% |
| Net Profit | -4.54 | 50.8% |
| OPM | — | |
| NPM | — | |
| EPS | -2.19 | 217.4% |
Nuwellis Reports Q1 2026 Net Sales Up 26% Y-o-Y
13 May 2026 · 13 May, 1:37 am
Summary
Nuwellis, Inc. announced its financial results for the first quarter ended March 31, 2026. Net sales increased by 26% to $2.4 million compared to the prior-year quarter. The gross margin improved significantly to 70.1%, reflecting better pricing, product mix, and the shift to contract manufacturing. The company also completed the acquisition of Rendiatech during the quarter, expanding its cardiorenal strategy.
Key Highlights
- 1
Nuwellis, Inc. reported a 26% increase in net sales, reaching $2.4 million compared to the prior-year period.
- 2
Gross margin improved to 70.1%, driven by improved pricing, product mix, and the transition to contract manufacturing.
- 3
The company completed the acquisition of Rendiatech, enhancing its product development portfolio with automated kidney-function monitoring capabilities.
- 4
Nuwellis expanded its commercial coverage with a new South Texas territory and the return of experienced sales leaders.
- 5
A new U.S. patent was issued supporting advanced safety design for pediatric extracorporeal therapy.
- 6
The company received a Notice of Allowance for a new patent covering its novel dual-lumen midline catheter technology.
Management Comments
John Erb
Q1 showed that the strategic reset we made in 2025 is beginning to translate into a more focused and commercially disciplined company. We are concentrating our resources around the areas where Nuwellis has clear clinical relevance, existing customer traction, and a differentiated path to growth, while maintaining the financial discipline required to execute. Aquadex gives us the foundation, pediatrics gives us a distinct growth category, and Rendiatech expands our ability to think more broadly across the cardiorenal continuum.
Informational and educational content only. Not investment advice.